14 Results for "

MDA-MB435

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "MDA-MB435" in MCE Product Catalog:

8
8 Cited Publications
Cat. No.: HY-12810
CAS No.: 1380432-32-5
Purity:  99.85%
Target:  

Ras

Research Areas:  

Cancer

EHop-016 is a potent and selective Rac GTPase Rac1 and Rac3 inhibitor. EHop-016 inhibits Rac1 activity with an IC50 of 1.1 μM in MDA-MB-435 cells. EHop-016 inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-79256
CAS No.: 863971-12-4
Synonyms: Monomethyl auristatin F methyl ester
Target:  

ADC Payloads

Research Areas:  

Cancer

MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4 -) cell lines, respectively.
loading...
    loading...
Cat. No.: HY-112338
CAS No.: 823828-18-8
Purity:  98.29%
Synonyms: CPD188
Target:  

STAT Apoptosis

Research Areas:  

Cancer

C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC50 of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC50s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .
loading...
    loading...
Cat. No.: HY-P4088
CAS No.: 850859-24-4
Target:  

Peptides

Research Areas:  

Cancer

LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics .
loading...
    loading...
Cat. No.: HY-W231513
CAS No.: 321945-24-8
Research Areas:  

Cancer

MASTL/Aurora A-IN-1 (Compound MA4) is a dual inhibitor of MASTL and Aurora A kinases with IC50 values of 0.56 μM and 0.16 μM, respectively. MASTL/Aurora A-IN-1 has broad-spectrum anticancer activity and has potent anticancer activity against SR (leukemia), K-562 (leukemia), MDA-MB-435 (melanoma), MOLT-4 (leukemia), and SK-MEL-2 (melanoma) cell lines in NCI-60 cancer cell lines with GI50 values of 0.023, 0.032, 0.037, 0.044, and 0.051 μM, respectively. MASTL/Aurora A-IN-1 inhibits Aurora A and MASTL kinases, inducing cell cycle G2/M arrest, thereby inhibiting cancer cell proliferation. MASTL/Aurora A-IN-1 can be used in cancer research, especially for tumors with dysregulated mitosis .
loading...
    loading...
Cat. No.: HY-178261
CAS No.: 1338494-49-7
Research Areas:  

Cancer

KT53 is a highly active, selective, and cell penetrable GSTO1 inhibitor. KT53 can effectively inhibit GSTO1 activity in MDA-MB-435 (IC50 = 35 nM) cells. KT53 significantly enhances the killing effect of cisplatin (HY-17394) on MDA-MB-435 cancer cells. KT53 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-P10790
CAS No.: 1332850-08-4
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively .
loading...
    loading...
Cat. No.: HY-178114
CAS No.: 3065966-31-3
Research Areas:  

Cancer

SKLB-0124 is a selective PRMT6 degrader with DC50s of 15.4 μM and a 16.4 μM in HCC827 and MDA-MB-435 cells. SKLB-0124 does not degrade PRMT1 or PRMT8. SKLB-0124 exhibits an IC50 on PRMT6 of 1.6 μM. SKLB-0124 induces proteasome dependent degradation of PRMT6 and significantly inhibits the proliferation. SKLB-0124 effectively induces apoptosis and cell cycle arrest. SKLB-0124 can be used for the studies of lung cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-U00002A
CAS No.: 257938-36-6
Target:  

VEGFR

Research Areas:  

Cancer

ZD-4190 hydrochloride is a potent VEGFR inhibitor with anti-tumor activity. ZD-4190 hydrochloride can delay the growth of MDA-MB-435 tumors by inhibiting tumor cell proliferation and angiogenesis .
loading...
    loading...
Cat. No.: HY-147556
CAS No.: 2396571-04-1
Target:  

Potassium Channel

Research Areas:  

Cancer

SK3 Channel-IN-1 (compound 7a) is a potent and specific SK3 channel modulator. SK3 Channel-IN-1 has efficient effect on breast cancer MDA-MB-435 cell migration while exhibiting low cytotoxicity in other cell lines. SK3 Channel-IN-1 can modulate ion channels’activity in cancer .
loading...
    loading...
Cat. No.: HY-120421
CAS No.: 1036759-00-8
Target:  

Sigma Receptor

Research Areas:  

Cancer

SW116 free base is a selective fluorescent ligand for sigma-2 receptor with a Ki of 14 nM. SW116 free base exhibits in methanol a maximal excitation wavelength of 333 nM, and a maximal emission wavelength of 506 nM. SW116 free base can be internalized into MDA-MB-435 cells, and reach 50% maximum fluorescent intensity in 24 minutes. SW116 free base can be as a fluorescent probe used in cancer research .
loading...
    loading...
Cat. No.: HY-N0985
CAS No.: 776325-66-7
1,4,5,6-Tetrahydroxy-7,8-diprenylxanthone is a xanthone that can be isolated from Garcinia xanthochymus. 1,4,5,6-Tetrahydroxy-7,8-diprenylxanthone shows moderate cytotoxicities against MDA-MB-435S and A549 cell lines with IC50s of 1.3 and 3.86 μg/ml, respectively .
loading...
    loading...
Cat. No.: HY-N16426
CAS No.: 1532554-02-1
Target:  

Parasite

Mycoleptone A is an azafluorenone compound. Mycoleptone A exhibits certain anti-leishmanial activity, with an LD50 of 28.5 μM against L. major. Mycoleptone A shows cytotoxicity against human prostate cancer cell line PC3, with an IC50 of 10.0 μM. Mycoleptone A can be used in research on anti-parasitic and anti-tumor aspects .
loading...
    loading...
Cat. No.: HY-155949
CAS No.: 931305-29-2
Research Areas:  

Neurological Disease Cancer

Bt354 is an orally active STAT3 inhibitor with IC50 values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain .
loading...
    loading...
  • 1